No Data
No Data
Kyan Technology (688687.SH): The application for marketing authorization of Pei integrated interferon α-2 injection for additional indications has been accepted.
Kain technology (688687.SH) announced on September 30th that it has recently received the 'Acceptance Notice' issued by the National Medical Products Administration. The company's innovative biological product, the pegylated interferon α-2 injection (trade name: Paiyisheng), has obtained the acceptance of the National Medical Products Administration for the application for the new indication of chronic hepatitis B in adults. The pegylated interferon α-2 injection is a recombinant interferon modified by PEG. The recombinant interferon is obtained by analyzing the integration following the principle of highest homology after sequence homology comparison of more than ten natural α-interferon subtypes. Its activity is higher than that of a
Kain Technology (688687.SH): Appoints He Chongfei as Chief Financial Officer.
Kain Technology (688687.SH) announced that the board of directors of the company recently received a written communication from the company's Chief Financial Officer, Guo Wei...
As of August 9, 2024, there were 7,098 shareholders in Kaien Technology (688687.SH) company.
On August 12, Gelonhui reported that as of August 9, 2024, there were 7,098 shareholders in Kaiyin Technology, according to the investor interaction platform.
Kaien Technology 2024 Interim Report
Kaien Technology's summary report for the first half of 2024.
Kaiyin Technology (688687.SH): the net income in the first half of the year is 42.4027 million yuan, a year-on-year growth of 10.54%.
On August 9th, Gelon Hui, Cainiao Technology (688687.SH) released its 2024 semi-annual report, achieving revenue of 0.597 billion yuan during the reporting period, a year-on-year increase of 4.89%; net income attributable to shareholders of the listed company was 42.4027 million yuan, a year-on-year increase of 10.54%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 44.6565 million yuan, a year-on-year increase of 6.84%; and the basic earnings per share was 0.25 yuan. During the reporting period, the company's operating income increased by 4.89% year-on-year, mainly due to the sales growth of Kailiwei products; net income attributable to shareholders of the listed company.
No Data
No Data